RC1416

DRUG3 trials

Sponsors

Nanjing RegeneCore Biotech Co., Ltd.

Conditions

Moderate to Severe AsthmaModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

A Phase Ib Study of RC1416 Injection

CompletedNCT06911866

Nanjing RegeneCore Biotech Co., Ltd.Moderate to Severe Asthma

Start: 2024-10-25End: 2025-09-25Updated: 2026-01-30

Phase 2

Phase II Study of RC1416 Injection in COPD

RecruitingNCT07402551

Nanjing RegeneCore Biotech Co., Ltd.Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Start: 2026-03-06End: 2028-08-30Target: 180Updated: 2026-09-08

Phase II Trial of RC1416 Injection in Asthma

RecruitingNCT07403487

Nanjing RegeneCore Biotech Co., Ltd.Moderate to Severe Asthma

Start: 2026-03-10End: 2028-02-28Target: 195Updated: 2026-09-10